TELANasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31

TELA Bio, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026

$0.97−0.00 (-0.48%)

Close on Oct 19, 2026

Market cap: $55.71M
P/E (TTM): –
Dividend yield: –

TELA Bio, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31
Revenue	80	69	58	41	29	18	15	8.27	4.25
Cost of Revenue	26	22	18	14	10	6.68	5.87	4.55	1.71
Gross Profit	54	46	40	27	19	11	9.27	2.94	2.53
Research & Development	9.22	8.81	9.62	8.94	6.74	4.26	4.15	4.34	5.79
Selling, General & Admin	79	79	75	57	42	32	24	19	14
Selling & Marketing	63	65	60	43	29	22	18	14	8.71
General & Administrative	16	15	15	14	12	10	6.22	4.90	4.96
Operating Expenses	88	88	84	66	48	37	28	21	19
Operating Income	-34	-34	-44	-39	-29	-25	-19	-18	-17
Interest Expense	5.25	5.29	5.22	4.05	3.60	3.56	3.61	1.80	4.56
Other Non-Operating Income	-4.85	-3.87	-2.59	-5.29	-3.83	-3.52	-3.26	-3.31	-4.41
Asset Impairment Charges	0	0	0	0	0	0	0	0	–
Gain (Loss) on Sale of Assets	–	7.58	0.01	–	0.00	–	–	0.00	-0.01
Legal Settlements	–	–	–	–	–	–	–	2.16	–
Pretax Income	-39	-38	-47	-44	–	–	–	–	–
Income Tax Expense	0.23	-0.14	–	–	–	–	–	–	–
Net Income incl. Noncontrolling Interests	-39	-38	-47	-44	-33	-29	-22	–	–
Net Income	-39	-38	-47	-44	-33	-29	-22	-21	-21
Net Income to Common	–	–	–	–	-33	-29	-30	-30	-27
EPS (Basic)(per share)	-0.83	-1.33	-2.04	-2.72	-2.30	-2.23	-17.10	-101.41	–
EPS (Diluted)(per share)	-0.83	-1.33	-2.04	-2.72	-2.30	-2.23	-17.10	-101.41	–
Shares Outstanding (Basic, Weighted)(shares)	47	29	23	16	14	13	1.77	0.29	0.29
Shares Outstanding (Diluted, Weighted)(shares)	47	29	23	16	14	13	1.77	0.29	0.29

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 67.8%
Operating margin: -42.6%
Net margin: -51.5%
Return on equity, FY2025: -223.4%

Financial strength

Current ratio: 2.99
Debt to equity: -3.53
Debt to assets: 93.9%
Cash to current liabilities: 167.0%

Valuation

P/E ratio: –
Price to sales: 0.70
Price to book: –
Dividend yield: –